Skip to main content
IDXXIDEXX Laboratories, Inc.Buy Wait5.5·$504.70-0.36%

IDEXX Laboratories (IDXX) Q2 2026 earnings — TrendMatrix coverage

BEAT+8.5% vs estimateEPS $4.27 vs $3.93 estCurrent verdict Buy (Wait) 5.5/10

Reported

Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure

Event detail · Q2 2026

Key numbers

Reported EPS
$4.27
Estimate
$3.93
Surprise
+8.5%
Revenue (period 2026-06-30)
$1.22B
Score today
5.5/10

Revenue source: xbrl.

Report record · Q2 2026

How the report landed

IDEXX Laboratories (IDXX) beat the $3.93 estimate with diluted EPS of $4.27 — a clear 8.5% upside surprise.

Current read · as of 2026-09-14

Where TrendMatrix's rating stands now

TrendMatrix currently rates IDXX Buy (Wait) at 5.5/10; no pre/post engine snapshot brackets this report.

4 of the last 4 quarters beat the estimate; this quarter's +8.5% surprise compares with a +5.8% four-quarter average. Next scheduled report: 2026-11-02.

What supports the rating

  • V7 flight-to-quality bonus: +0.5 (Q=8.4 in RISK_OFF)
  • Sector modifier (Healthcare): +0.5

What argues against it

  • Concentration risk — Supplier: Ortho-Clinical Diagnostics
  • Negative momentum
  • Below 200-MA, MA slope -2.8%/30d (confirmed downtrend)

This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.

Current engine read

The levels TrendMatrix's engine tracks

Current price
$504.70
Entry target
$491.16
Price target
$608.06
Stop
$464.08
Upside to target
+20.5%
Reward-to-risk
3.8:1

At 35.5× trailing and 30.1× forward earnings, consensus estimates imply little change in earnings power.

Risk check: RSI 24 — a level conventionally read as oversold.

Model outputs from TrendMatrix’s engine as of 2026-09-14 — shown for context, not personalized investment advice.

Healthcare context

IDXX at TrendMatrix's latest read

Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.

Industry
Diagnostics & Research
Market cap
$39.76B
P/E (fwd)
30.1
P/E (ttm)
35.5
52-week range
$500.61$769.98
Off 52-week high
34.5%
RSI (14)
24
Volume vs avg
0.80×
Score today
5.5/10

Earnings figures are sourced from TrendMatrix’s pipeline (EPS: existing earnings extraction; revenue: SEC XBRL company facts where available, yfinance-provisional otherwise). Not a buy/sell rating, a price target, or investment advice — see the current verdict on the stock’s main page for TrendMatrix’s live read.

Home Stocks IDXX Earnings Q2 2026 earnings